News

The European Commission is expected to make a decision about the application before the end of June.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The prevalence of AMD features in Republic of Korea Air Force pilots was higher than in other general populations studied.

Solar retinopathy is caused by prolonged or high intensity exposure of the fovea centralis to light energy. Suspected cases of solar retinopathy may require urgent referral to an ophthalmologist for diagnosis, and to eliminate treatable causes for central visual disturbance.

In a recent study led by Steven Pittler, PhD, and his team at the University of Alabama Birmingham (UAB), the role of modifier genes in retinitis pigmentosa type 59 (RP59) was meticulously examined.

The company noted that individuals can purchase the ARx AI headset and register for access to the Seeing AI app through the provided links or download the latest version of the NaviLens app.

Viewing the solar eclipse without proper eye protection can pose hazards, and ophthalmologists can educate patients about the importance of using certified solar viewing glasses or other safe viewing methods.

New members bring a wealth of experience and expertise from various sectors within the ophthalmology, pharmaceutical, and healthcare fields, further strengthening the Ophthalmology Foundation's mission.

Research estimates that the RVO market with see a compound annual growth rate of 11.9%.

With 37 years of clinical trial experience, Peter J. McDonnell, MD, offer some tips.

The investigators explained that the survival rate of patients with retinoblastoma has improved significantly as a result of intra-arterial chemotherapy and enucleation surgery.

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.

A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.

An investigation is set to launch on SpaceX’s 30th Commercial Resupply Services mission to the International Space Station contracted by NASA to test the therapy in space.

It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).

Gildeuretinol halts Stargardt disease progression for up to 6 years.

Andrew G. Lee, MD, outlines his stance on whether all patients with idiopathic intracranial hypertension should have a lumbar puncture, emphasizing clinical judgment and treatment strategies.

The International Headache Society has provided criteria for visual snow syndrome (VSS).

Observing potential cases highlights the importance of monitoring and reporting, contributing to a comprehensive understanding of therapeutic effects.

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.

Ophthalmologists can educate their patients about the importance of using certified solar viewing glasses or other safe viewing methods.

When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

OCU410 is a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age related macular degeneration.

The collaboration combines Clario's transformative technology with Cleveland Clinic's market-leading imaging expertise and AI-enabled analysis to help bring new therapies to patients, faster.